StockpollyBeta
Get App
Popularity #2,671
ARTV · NASDAQ · Biotechnology

Artiva Biotherapeutics (ARTV)

Develops cryopreserved allogeneic NK-cell candidates for autoimmune diseases and cancer.

$8.09
After hours−0.01 (−0.06%)
At close$8.10(+3.38%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2720000000000
Cost of revenue000000000010
Gross profit27200000000−10
161415161818222323222427
Research & development131111121413171818171922
334455555555
General & administrative334455555555
Other expenses0000000000−10
Operating income11−12−14−16−18−18−22−23−23−22−24−27
001−219221112
Interest income011122221112
Other non-operating income00−12−1−9−2−2−1−1−1−2
Income before tax11−12−14−18−17−9−20−21−22−21−24−25
Income tax expense000000000000
Net income from continuing operations11−12−14−18−17−9−20−21−22−21−24−25
Net income11−12−14−18−17−9−20−21−22−21−24−25
EPS, basic$0.59−$0.54−$0.79−$0.62−$0.92−$0.82−$0.83−$0.87−$0.88−$0.85−$0.95−$0.63
EPS, diluted$0.59−$0.54−$0.79−$0.62−$0.92−$0.82−$0.83−$0.87−$0.88−$0.85−$0.95−$0.63
Weighted average shares, basic192018232424242424242539
Weighted average shares, diluted192018232424242424242539
EBITDA12−11−13−17−17−9−20−21−21−20−23−24
Depreciation & amortization111111111111
EBIT11−12−14−18−17−9−20−21−22−21−24−25